JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB289734

Recombinant Mouse Apolipoprotein CI/Apo-CI

Be the first to review this product! Submit a review

|

(0 Publication)

Recombinant Mouse Apolipoprotein CI/Apo-CI is a Mouse Fragment protein, in the 27 to 88 aa range, expressed in Cell free, with >90%, suitable for SDS-PAGE.
1 Images
SDS-PAGE - Recombinant Mouse Apolipoprotein CI/Apo-CI (AB289734)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant Mouse Apolipoprotein CI/Apo-CI (AB289734)

SDS-PAGE analysis of ab289734

Key facts

Purity

>90% SDS-PAGE

Expression system

Cell free

Tags

His tag N-Terminus

Applications

SDS-PAGE

applications

Biologically active

No

Accession

P34928-1

Animal free

Yes

Carrier free

No

Species

Mouse

Storage buffer

pH: 7.4 - 8 Constituents: 6% Trehalose, 0.12% Tris, 0.037% Ethylenediaminetetraacetic acid, disodium, dihydrate

storage-buffer

style
left-column

Complementary Products

Proteins & Peptides

AB316480

Recombinant Syntaxin 1a Protein Standard (His tag)

Sandwich ELISA - Recombinant Syntaxin 1a Protein Standard (His tag) (AB316480)

  • 0
  • 0
Proteins & Peptides

AB280330

Recombinant human Apolipoprotein E3

Mass Spectrometry - Recombinant human Apolipoprotein E3 (AB280330)

  • 0
  • 0
Proteins & Peptides

AB51435

Recombinant human Aurora B protein (GST tag N-Terminus)

Functional Studies - Recombinant human Aurora B protein (AB51435)

  • 0
  • 0
Proteins & Peptides

AB70619

Recombinant human PBK/SPK protein (GST tag N-Terminus)

SDS-PAGE - Recombinant human PBK/SPK protein (AB70619)

  • 0
  • 0
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column
style
left-column

Sequence info

[{"linker":null,"sequence":"APDLSGTLESIPDKLKEFGNTLEDKARAAIEHIKQKEILTKTRAWFSEAFGKVKEKLKTTFS","proteinLength":"Fragment","predictedMolecularWeight":"12.5 kDa","actualMolecularWeight":null,"aminoAcidEnd":88,"aminoAcidStart":27,"nature":"Recombinant","expressionSystem":"Cell free","accessionNumber":"P34928","tags":[{"tag":"His","terminus":"N-Terminus"}]}]
style
left-column

Properties and storage information

Form
Lyophilized
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
False
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Apolipoprotein CI (Apo-CI) plays a mechanical role in lipid metabolism where it acts as an inhibitor of lipoprotein lipase and hepatic lipase hindering lipolytic activity. It is also known as 'apo 250' and 'apo atv20' with a molecular mass of approximately 6.6 kDa. Apo-CI is primarily expressed in the liver and secreted into the plasma where it associates with high-density lipoproteins (HDL) and very low-density lipoproteins (VLDL).
Biological function summary

Apo-CI influences plasma triglyceride levels and cholesterol homeostasis. It plays a role in lipid transport and metabolism by modulating the binding of other apolipoproteins such as apo A-IV and interfering with the binding of lipoproteins to their receptors. Apo-CI is part of a complex of apolipoproteins that regulate lipid metabolism working in tandem to balance lipid and cholesterol levels in the body.

Pathways

Apo-CI is actively involved in the lipoprotein metabolism pathway and cholesterol efflux pathway. These pathways are important in maintaining lipid balance and cardiovascular health. Apo-CI is related to other apolipoproteins within these pathways such as apo E and apo A-I. Its function in modulating lipoprotein receptor interactions aligns with the broader mechanisms of these pathways in lipid and cholesterol regulation.

Elevated levels of Apo-CI are associated with hyperlipidemia and cardiovascular disease. These conditions may result from its inhibitory effects on lipase activity leading to increased triglyceride levels. Apo-CI's interaction with other apolipoproteins such as apo B and apo E is linked to its role in the pathogenesis of these disorders. Understanding Apo-CI's involvement in these diseases can guide therapeutic strategies aimed at regulating its expression and function.
style
left-column

Product protocols

style
left-column

Target data

Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein (By similarity). Binds free fatty acids and reduces their intracellular esterification.
See full target information Apoc1

Alternative Names

Apolipoprotein C-I, Apo-CI, ApoC-I, Apolipoprotein C1, Apoc1
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com